Circulating CC16, immune response to Mycoplasma pneumoniae and lung function deficits: a population-based, multi-cohort study.

IF 3.5 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Respiratory medicine Pub Date : 2025-03-14 DOI:10.1016/j.rmed.2025.108044
Alane Blythe C Dy, Nipasiri Voraphani, Amber Spangenberg, Steven A Belinsky, Maria A Picchi, Erik Melén, Inger Kull, Angela Simpson, Clare Murray, Marilyn Halonen, Julie G Ledford, Stefano Guerra
{"title":"Circulating CC16, immune response to Mycoplasma pneumoniae and lung function deficits: a population-based, multi-cohort study.","authors":"Alane Blythe C Dy, Nipasiri Voraphani, Amber Spangenberg, Steven A Belinsky, Maria A Picchi, Erik Melén, Inger Kull, Angela Simpson, Clare Murray, Marilyn Halonen, Julie G Ledford, Stefano Guerra","doi":"10.1016/j.rmed.2025.108044","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sufficient levels of club cell secretory protein (CC16) are essential to protect against lung function impairments. Experimental studies have demonstrated that CC16 modulates inflammatory responses and protects against airway hyperresponsiveness following Mycoplasma pneumoniae (Mp) infection. Individuals with asthma have low CC16 levels and increased susceptibility to Mp infection. Here we determine whether low CC16 and Mp seropositivity have combined effects on lung function deficits predisposing to airflow limitation, particularly in asthma.</p><p><strong>Methods: </strong>Serum levels of CC16 and IgG antibodies against Mp (MpIgG) were measured in adult participants from cohorts BAMSE, MAAS, LSC, and TESAOD. Participants were then stratified into four groups: normal CC16/MpIgG-, normal CC16/MpIgG+, low CC16/MpIgG-, low CC16/MpIgG+. Associations between these groups and lung function (FEV<sub>1</sub> and FEV<sub>1</sub>/FVC) were assessed by linear regression, adjusting for covariates,. Meta-analyzed estimates were calculated.</p><p><strong>Results: </strong>Low CC16 was associated with decreased lung function in the total population, but no combined effects of CC16 and MpIgG were observed. Among asthmatic participants, the low CC16/MpIgG+ group had remarkably lower of FEV<sub>1</sub>/FVC z-scores (-0.84, CI: -1.29, -0.38) compared to the reference group, and Mp seropositivity was associated with significant deficits in FEV<sub>1</sub>/FVC z-scores among those with low CC16 (-0.60, CI: -1.08, -0.12), but not among those with normal CC16 (-0.10, CI: -0.56, 0.36).</p><p><strong>Conclusion: </strong>This suggests that individuals with asthma with low levels of CC16 combined with a history of Mp infection may be more susceptible to deficits in FEV<sub>1</sub>/FVC, the hallmark of airflow limitation, emphasizing the need for prospective studies designed to test this hypothesis.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"108044"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.rmed.2025.108044","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Sufficient levels of club cell secretory protein (CC16) are essential to protect against lung function impairments. Experimental studies have demonstrated that CC16 modulates inflammatory responses and protects against airway hyperresponsiveness following Mycoplasma pneumoniae (Mp) infection. Individuals with asthma have low CC16 levels and increased susceptibility to Mp infection. Here we determine whether low CC16 and Mp seropositivity have combined effects on lung function deficits predisposing to airflow limitation, particularly in asthma.

Methods: Serum levels of CC16 and IgG antibodies against Mp (MpIgG) were measured in adult participants from cohorts BAMSE, MAAS, LSC, and TESAOD. Participants were then stratified into four groups: normal CC16/MpIgG-, normal CC16/MpIgG+, low CC16/MpIgG-, low CC16/MpIgG+. Associations between these groups and lung function (FEV1 and FEV1/FVC) were assessed by linear regression, adjusting for covariates,. Meta-analyzed estimates were calculated.

Results: Low CC16 was associated with decreased lung function in the total population, but no combined effects of CC16 and MpIgG were observed. Among asthmatic participants, the low CC16/MpIgG+ group had remarkably lower of FEV1/FVC z-scores (-0.84, CI: -1.29, -0.38) compared to the reference group, and Mp seropositivity was associated with significant deficits in FEV1/FVC z-scores among those with low CC16 (-0.60, CI: -1.08, -0.12), but not among those with normal CC16 (-0.10, CI: -0.56, 0.36).

Conclusion: This suggests that individuals with asthma with low levels of CC16 combined with a history of Mp infection may be more susceptible to deficits in FEV1/FVC, the hallmark of airflow limitation, emphasizing the need for prospective studies designed to test this hypothesis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
背景:足够水平的会厌细胞分泌蛋白(CC16)对防止肺功能损伤至关重要。实验研究表明,CC16 可调节炎症反应,并在肺炎支原体(Mp)感染后防止气道高反应性。哮喘患者的 CC16 水平较低,对 Mp 感染的易感性增加。在此,我们要确定低 CC16 和 Mp 血清阳性是否会共同影响易导致气流受限的肺功能缺陷,尤其是在哮喘患者中:方法:测量 BAMSE、MAAS、LSC 和 TESAOD 等队列中成年参与者血清中 CC16 和 Mp IgG 抗体(MpIgG)的水平。然后将参与者分为四组:正常 CC16/MpIgG-、正常 CC16/MpIgG+、低 CC16/MpIgG-、低 CC16/MpIgG+。这些组别与肺功能(FEV1 和 FEV1/FVC)之间的关系通过线性回归进行评估,并对协变量进行调整。计算了元分析估计值:结果:在所有人群中,低 CC16 与肺功能下降有关,但未观察到 CC16 和 MpIgG 的联合效应。在哮喘患者中,与参照组相比,低 CC16/MpIgG+ 组的 FEV1/FVC z 评分明显较低(-0.84,CI:-1.29,-0.38),而在低 CC16 患者中,Mp 血清阳性与 FEV1/FVC z 评分的显著下降有关(-0.60,CI:-1.08,-0.12),但在正常 CC16 患者中则无关(-0.10,CI:-0.56,0.36):这表明,CC16 水平低且有 Mp 感染史的哮喘患者可能更容易出现 FEV1/FVC 缺陷,而 FEV1/FVC 是气流受限的标志。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respiratory medicine
Respiratory medicine 医学-呼吸系统
CiteScore
7.50
自引率
0.00%
发文量
199
审稿时长
38 days
期刊介绍: Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.
期刊最新文献
Relationship between Sputum Bacterial Load and Lung Function in Children with Cystic Fibrosis Receiving Tobramycin. The Use of Specialist Palliative Care Services Differs in Chronic Obstructive Pulmonary Disease and Interstitial Lung Disease: a National Cohort Study. Circulating CC16, immune response to Mycoplasma pneumoniae and lung function deficits: a population-based, multi-cohort study. Effects of different degrees of anthracosis on pleural structure: A preliminary exploratory study Corrigendum to "Optimising outcomes for adults with Cystic Fibrosis taking CFTR modulators by individualising care: Personalised data linkage to understand treatment optimisation (PLUTO), a novel clinical framework" [Respirat. Med. 239 (2025)].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1